Clinical and Applied Thrombosis/Hemostasis · 2014 · 17 citations · 18 references
MedicinePharmacologyPharmacotherapyHemostasisPediatric Clinical PharmacologyPediatric HematologyCoagulation AbnormalitiesCoagulation DisordersCoagulation Factor DeficienciesHemostatic AgentsClinical Safety EvaluationCoagulationFactor ViiaInherited Coagulation Factor DeficienciesProthrombin Complex Concentrate UseRecombinant Activated Factor Vii
In order to establish the efficacy and biosimilar nature of AryoSeven to NovoSeven in the treatment of congenital factor VII (FVII) deficiency, patients received either agent at 30 μg/kg, intravenously per week for 4 weeks, in a randomized fashion. The primary aim was to compare FVII:coagulation activity (FVII:C), 20 minutes after recombinant activated FVII (rFVIIa) injection, in the 2 groups. A secondary measure was self-reported bleeding. The median interquartile baseline range of the plasma level of activated FVII (FVIIa) activity in the 2 groups was 1.6 (1.1-14.0) IU/dL and 5.0 (1.1-25.5) IU/dL. All patients achieved levels of FVIIa (FVII:C) >30 IU/dL, 20 minutes after the injection of rFVIIa. Bleeding was similar between the 2 groups, with a comparable decrease in severity and frequency compared to the last month prior to treatment. AryoSeven is similar to NovoSeven in increasing postinjection FVIIa activity as well as in clinical safety and efficacy.
18
Clinical phenotypes and factor VII genotype in congenital factor VII deficiency
Guglielmo Mariani, Falko H. Herrmann, Alberto Dolce et al. · Thrombosis and Haemostasis · 2005 · 257 citations
Medicine, Genetics, Hematology +17
Inherited Factor VII Deficiency: Molecular Genetics and Pathophysiology
D.N. Cooper, David Millar, Adam Wacey et al. · Thrombosis and Haemostasis · 1997 · 159 citations
Margaret V. Ragni, Jessica H. Lewis, Joel A. Spero et al. · American Journal of Hematology · 1981 · 153 citations
Medicine, Hematology, Hemostasis +15